-Reuters
Rezolute To Initiate A Pivotal Phase 3 Study Of RZ358 in Participants 3 Months Of Age And Older With Congenital Hyperinsulinism
Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025
Conference call scheduled today at 4:30 p.m. ET
REDWOOD CITY, Calif., June 27,